Tech Company Financing Transactions

Twentyeight-Seven Therapeutics Funding Round

On 9/7/2018, Twentyeight-Seven Therapeutics received $65 million in Series A investment from MPM Capital, Novartis Venture Fund and Astellas Venture Capital.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

490 Arsenal Way 100B
Watertown, MA 02472
USA

Phone

(617) 603-6060

Website

www.twentyeight-seven.com

Email Address

[email protected]

Overview

Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases. By targeting ncRNA modulating proteins (RMPs), we can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Kazumi Shiosaki

        

Chief Scientific Officer

Shomir Ghosh

        

VP - Bus. Development

Reid Leonard

        

VP - R & D

Ross Stein

        

Browse more venture capital transactions:

Prev: 9/7/2018: MIRROR venture capital transaction
Next: 9/7/2018: PagerDuty venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary